Related Experiment Video
Updated: Aug 5, 2026

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
Efficacy and Safety of Zizhu Ointment for Wagner Grade 2 Diabetic Foot Ulcers: A Single-Center, Randomized,
Xiao-Yu Li1, Guo-Bin Liu1, Yang You1
1Department of Vascular Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Objective:
To evaluate the clinical efficacy and safety of Zizhu Ointment (ZZO) in treating Wagner grade 2 diabetic foot ulcers (DFUs).
Methods:
In this single-center, randomized, double-blind, placebo-controlled trial, using SPSS 26.0, a computer-generated random number sequence was used to randomly assign 154 patients with Wagner grade 2 DFUs in a 1:1 ratio to either the ZZO group (n=77) or the placebo control group (n=77). Both groups received conventional therapy and standard debridement. Patients received the assigned intervention as a topical application for 6 weeks, followed by a 6-week follow-up period. The primary outcome was the ulcer healing rate at 6 weeks. Secondary outcomes included Chinese medicine (CM) syndrome scores, transcutaneous oxygen pressure (TcPO2), wound blood flow, and safety indicators.
Results:
After 6 weeks, the ulcer healing rate was significantly higher in the ZZO group than in the placebo control group (67.59% ± 22.69% vs. 28.81% ± 15.80%, P<0.001). This superiority was maintained at the end of the 6-week follow-up (80.95% ±19.16% vs. 42.20% ±21.93%, P<0.001). The ZZO group also demonstrated significantly greater improvements in reducing ulcer area and depth, improving CM syndrome scores, TcPO2, and wound blood flow (all P<0.05). The incidence of adverse events was comparable between the two groups (P>0.05).
Conclusions:
ZZO effectively promotes the healing of Wagner grade 2 DFUs, ameliorates the wound microenvironment and CM symptoms, and exhibits a favorable safety profile. (Registration No. ITMCTR2025000126).